Identification of pre-diabetes using a combination of mean glucose and 1,5-anhydroglucitol markers
AssigneeGlycoMark Inc.
InventorsEric A. Button, Robert Scott Foster
Life of this patent
Estimating the term…
Abstract
Described herein is a method for determining the disease state in a patient using combined mean glucose measurements and 1,5-anhydroglucitol to identify individuals at risk for developing diabetes. The ratio of mean glucose measurements to 1,5-anhydroglucitol correlates significantly better to maximal levels of postmeal glucose levels and related measurements, than mean glucose measurements or 1,5-anhydroglucitol correlate independently.
Claims12
A method for detecting a disease-state in a patient comprising
- (a) determining the mean glucose concentration;
- (b) determining the 1,5-anhydroglucitol concentration;
- and
- (c) calculating a ratio of the measurements of (a) to (b).
A method for method for detecting a disease-state in a patient comprising
- (a) determining the mean glucose concentration;
- (b) determining the 1,5-anhydroglucitol concentration;
- and
- (c) calculating a ratio of the measurements of (a) to (b),
- wherein the mean glucose concentration is determined using any one of hemoglobin A1C, fructosamine, glycated albumin, fingerstick measurements, or continuous glucose monitoring;
- and
- wherein the disease-state is pre-diabetes, early-stage diabetes, diabetes, diabetes-associated microvascular disease, or diabetes-associated macrovascular disease.
The method of claim 8, wherein the ratio of mean glucose concentration to 1,5-anhydroglucitol concentration is combined with additional disease-state markers selected from the group consisting of adiponectin levels, insulin levels, or fasting glucose levels
- wherein the identification of pre-diabetes, early-stage diabetes, diabetes, diabetes-microvascular disease, or diabetes-macrovascular disease is enhanced.
A method for determining the effectiveness of treatment for a disease-state comprising
- (a) determining the mean glucose concentration;
- (b) determining the 1,5-anhydroglucitol concentration;
- and
- (c) calculating a ratio of the measurements of (a) to (b),
- wherein the mean glucose concentration is determined using any one of hemoglobin A1C, fructosamine, glycated albumin, fingerstick measurements, or continuous glucose monitoring;
- and
- wherein the disease-state is pre-diabetes, early-stage diabetes, diabetes, diabetes-associated microvascular disease or diabetes-associated macrovascular disease.
The method of claim 10, wherein the ratio of mean glucose concentration to 1,5-anhydroglucitol concentration is combined with additional disease-state markers selected from the group consisting of adiponectin levels, insulin levels, or fasting glucose levels
- wherein the identification of pre-diabetes, early-stage diabetes, diabetes, diabetes-microvascular disease, or diabetes-macrovascular disease is enhanced.
A kit for detecting a disease-state in a patient comprising means for
- (a) determining the mean glucose concentration;
- (b) determining the 1,5-anhydroglucitol concentration;
- and
- (c) calculating a ratio of the measurements of (a) to (b),
- wherein the mean glucose concentration is determined using any one of hemoglobin A1C, fructosamine, glycated albumin, fingerstick measurements, or continuous glucose monitoring;
- and
- wherein the disease-state is pre-diabetes, early-stage diabetes, diabetes, diabetes-associated microvascular disease, or diabetes-associated macrovascular disease.
The kit of claim 12, comprising additional disease-state measurements selected from the group consisting of adiponectin levels, insulin levels, or fasting glucose levels, wherein the identification of pre-diabetes, early-stage diabetes, diabetes, diabetes-microvascular disease, or diabetes-macrovascular disease is enhanced.
Dependencies are inferred from the claim text.